Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Increasing clinical investigations have explored the value of EGFR-TKIs plus antiangiogenic drugs as the first-line treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fei, Chen, Naifei, Yu, Yu, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344312/
https://www.ncbi.nlm.nih.gov/pubmed/32714857
http://dx.doi.org/10.3389/fonc.2020.00904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344312/
https://www.ncbi.nlm.nih.gov/pubmed/32714857
http://dx.doi.org/10.3389/fonc.2020.00904

Ejemplares similares